This Phase II safety and efficacy trial consisted of three Stages : Stage A and B studies were an expansion of Phase I involving 10 and 90 subjects respectively , and Stage C was then conducted in two parts ( high dose and low dose ) , each enrolling 80 participants : 20 borderline lepromatous/lepromatous ( BL/LL ) leprosy patients , 20 borderline tuberculoid/tuberculoid ( BT/TT ) leprosy patients , 20 household contacts of leprosy patients ( HC ) , and 20 tuberculosis ( TB ) patients .